Simagchem Corporation | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 13806087780 | |||
![]() |
sale@simagchem.com | |||
Chemical manufacturer since 2002 | ||||
chemBlink standard supplier since 2008 | ||||
BrightGene Bio-medical Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (512) 6255-1801 6255-1767 +86 13812696362 | |||
![]() |
kevinwan@bright-gene.com kevinwan0203@gmail.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2001 | ||||
chemBlink standard supplier since 2009 | ||||
Taizhou Crene Biotechnology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (576) 8881-3233 8820-5808 +86 13396860566 | |||
![]() |
order@pharm-intermediates.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2011 | ||||
chemBlink standard supplier since 2009 | ||||
MED CAN Medical Technology (Beijing) Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (10) 6336-0311 | |||
![]() |
sales@medcan.com.cn | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2009 | ||||
ZHIYU Biotechnology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (512) 6279-1916 | |||
![]() |
sales@zhiyubiotech.com info@zhiyubiotech.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2008 | ||||
chemBlink standard supplier since 2009 | ||||
Hefei TNJ Chemical Industry Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (551) 6541-8684 | |||
![]() |
sales@tnjchem.com | |||
Chemical manufacturer since 2001 | ||||
chemBlink standard supplier since 2010 | ||||
Shanghai Biochempartner Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (27) 5923-9227 | |||
![]() |
2323744551@qq.com | |||
Chemical distributor since 2012 | ||||
chemBlink standard supplier since 2010 | ||||
BOC Sciences | USA | Inquire | ||
---|---|---|---|---|
![]() |
+1 (631) 485-4226 | |||
![]() |
info@bocsci.com | |||
Chemical manufacturer | ||||
chemBlink standard supplier since 2010 | ||||
Classification | API >> Antiparasitic drug >> Anthelmintic medications |
---|---|
Name | Doramectin |
Synonyms | (1'R,2R,3S,4'S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-2-cyclohexyl-21',24'-dihydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one |
Molecular Structure | ![]() |
Molecular Formula | C50H74O14 |
Molecular Weight | 899.11 |
CAS Registry Number | 117704-25-3 |
EC Number | 601-490-4 |
SMILES | C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C8CCCCC8)C)O |
Density | 1.3±0.1 g/cm3, Calc.* |
---|---|
Index of Refraction | 1.580, Calc.* |
Boiling Point | 967.4±65.0 ºC (760 mmHg), Calc.* |
Flash Point | 274.4±27.8 ºC, Calc.* |
* | Calculated using Advanced Chemistry Development (ACD/Labs) Software. |
Hazard Symbols |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H300-H301-H302-H360-H361-H362-H370-H372-H400-H410 Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Precautionary Statements | P203-P260-P263-P264-P270-P273-P280-P301+P316-P301+P317-P308+P316-P318-P319-P321-P330-P391-P405-P501 Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hazard Classification | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SDS | Available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Doramectin, a member of the avermectin class of compounds, was discovered through research efforts aimed at developing novel antiparasitic agents. It was first synthesized and characterized by scientists at Merck & Co. in the late 1980s. The discovery of doramectin stemmed from the screening of fermentation products derived from Streptomyces avermitilis, a soil bacterium known for producing potent anthelmintic compounds. Doramectin emerged as a promising candidate due to its potent antiparasitic activity and favorable pharmacokinetic properties. Doramectin is widely used in veterinary medicine for the treatment and control of parasitic infections in livestock, including cattle, sheep, and swine. It is effective against a broad spectrum of internal and external parasites, including gastrointestinal nematodes, lungworms, mites, and ticks. Doramectin's efficacy in controlling parasitic infections contributes to improved animal health and productivity in livestock farming operations. In addition to livestock, doramectin is also used in companion animals, particularly in dogs and horses, for the prevention and treatment of parasitic infestations. It is effective against common parasites such as heartworms, intestinal worms, mites, and ticks. Doramectin formulations for companion animals are available in various formulations, including oral and topical preparations. Doramectin's broad spectrum of activity extends to wildlife species susceptible to parasitic infections. Wildlife conservationists and veterinarians utilize doramectin to control parasites in captive and free-ranging wildlife populations, contributing to the preservation of biodiversity and ecosystem health. The control of parasites in livestock and companion animals with doramectin also has indirect benefits for public health. By reducing the prevalence of zoonotic parasites and limiting the spread of parasitic diseases from animals to humans, doramectin plays a role in safeguarding public health and minimizing the risk of transmission of parasitic infections. References 2016. Finafloxacin. Pharmaceutical Substances. URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-06-0134 2020. Synthetic Approaches to Contemporary Drugs that Contain the Cyclopropyl Moiety. Synthesis, 52(11). DOI: 10.1055/s-0039-1690058 |
Market Analysis Reports |
List of Reports Available for Doramectin |